Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) accounts for 10% of hematologic malignancies. CLL is a malignancy of CD5+ B cells and it is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues. In the present case, a middle-...

Descripción completa

Detalles Bibliográficos
Autores principales: Maharaj, Dipnarine, Srinivasan, Gayathri, Abreu, Maria M., Ko, Meng-Wei, Jewett, Anahid, Gouvea, Jacqueline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822209/
https://www.ncbi.nlm.nih.gov/pubmed/33375215
http://dx.doi.org/10.3390/cells10010010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822209/
https://www.ncbi.nlm.nih.gov/pubmed/33375215
http://dx.doi.org/10.3390/cells10010010

Ejemplares similares